The final, formatted version of the article will be published soon.
CLINICAL TRIAL article
Front. Immunol.
Sec. Viral Immunology
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1443665
This article is part of the Research Topic Systemic immune response through a multi-omic lens View all articles
A clinical protocol for a German birth cohort study of the Maturation of Immunity Against respiratory viral Infections (MIAI)
Provisionally accepted- 1 University Hospital Würzburg, Würzburg, Bavaria, Germany
- 2 Hannover Medical School, Hanover, Lower Saxony, Germany
- 3 University of Geneva, Geneva, Geneva, Switzerland
- 4 Institute of Experimental Virology, Twincore Center for Experimental and Clinical Infection Research GmbH, Hannover, Germany
- 5 Julius Maximilian University of Würzburg, Würzburg, Bavaria, Germany
- 6 Max Delbrück Center for Molecular Medicine, Helmholtz Association of German Research Centers (HZ), Berlin, Baden-Wurttemberg, Germany
- 7 University of Freiburg, Freiburg, Baden-Wurttemberg, Germany
- 8 University of Bonn, Bonn, North Rhine-Westphalia, Germany
Respiratory viral infections (RVIs) are a major global contributor to morbidity and mortality. The susceptibility and outcome of RVIs are strongly age-dependent and show considerable interpopulation differences, pointing to genetically and/or environmentally driven developmental variability. The factors determining the age-dependency and shaping the age-related changes of human anti-RVI immunity after birth are still elusive. We are conducting a prospective birth cohort study aiming at identifying endogenous and environmental factors associated with the susceptibility to RVIs and their impact on cellular and humoral immune responses against the influenza A virus (IAV), respiratory syncytial virus (RSV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The MIAI birth cohort enrolls healthy, full-term neonates born at the University Hospital Würzburg, Germany, with follow-up at four defined time-points during the first year of life. At each study visit, clinical metadata including diet, lifestyle, sociodemographic information, and physical examinations, are collected along with extensive biomaterial sampling. Biomaterials are used to generate comprehensive, integrated multi-omics datasets including transcriptomic, epigenomic, proteomic, metabolomic and microbiomic methods. The results are expected to capture a holistic picture of the variability of immune trajectories with a focus on cellular and humoral key players involved in the defense of RVIs and the impact of host and environmental factors thereon. Thereby, MIAI aims at providing insights that allow unraveling molecular mechanisms that can be targeted to promote the development of competent anti-RVI immunity in early life and prevent severe RVIs.
Keywords: Birth cohort, Respiratory Viral Infection, IAV, RSV, SARS-CoV-2, Multi-omics data, anti-viral immunity, microbiota
Received: 05 Jun 2024; Accepted: 29 Aug 2024.
Copyright: © 2024 Hartmann, Khan, Schöning, Richter, Willers, Pirr, Heckmann, Dirks, Morbach, Konrad, Fries, Winkler, Büchel, Seidenspinner, Fischer, Vollmuth, Meinhardt, Marissen, Schmolke, Haid, Pietschmann, Backes, Dölken, Löber, Keil, Heuschmann, Wöckel, Sagar, Ulas, Forslund, Härtel and Viemann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Dorothee Viemann, University Hospital Würzburg, Würzburg, 97080, Bavaria, Germany
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.